ZYTIGA® (abiraterone acetate)
ZYTIGA - COU-AA-301 Study

SUMMARY

A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:

- ZYTIGA® (abiraterone acetate) - COU-AA-301 Study
  - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below



Note: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; CI, confidence interval; CYP17, cytochrome P450 17α-hydroxylase/17,20-lyase; HR, hazard ratio; IA, interim analysis; LFT, liver function test; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PO, orally; PSA, prostate-specific antigen; QD, once daily; R, randomization; ULN, upper limit of normal; UTI, urinary tract infection.